Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Common Equity: 2010-2025

Historic Common Equity for Cytokinetics (CYTK) over the last 14 years, with Sep 2025 value amounting to -$521.1 million.

  • Cytokinetics' Common Equity fell 3646.12% to -$521.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$521.1 million, marking a year-over-year decrease of 3646.12%. This contributed to the annual value of -$135.4 million for FY2024, which is 64.96% up from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Common Equity is -$521.1 million, which was down 41.33% from -$368.7 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Common Equity peaked at $249.0 million during Q3 2021, and registered a low of -$521.1 million during Q3 2025.
  • Moreover, its 3-year median value for Common Equity was -$333.1 million (2023), whereas its average is -$270.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 575.69% in 2022, then crashed by 3,646.12% in 2025.
  • Quarterly analysis of 5 years shows Cytokinetics' Common Equity stood at $243.9 million in 2021, then tumbled by 144.25% to -$107.9 million in 2022, then tumbled by 258.04% to -$386.3 million in 2023, then soared by 64.96% to -$135.4 million in 2024, then tumbled by 3,646.12% to -$521.1 million in 2025.
  • Its Common Equity stands at -$521.1 million for Q3 2025, versus -$368.7 million for Q2 2025 and -$266.4 million for Q1 2025.